Responses
Regular and Young Investigator Award Abstracts
Clinical Trials Completed
382 The synthetic long peptide cancer vaccine UV1 in combination with ipilimumab induces a CD4+ Th1 anti-hTERT immune response and an inflammatory tumor microenvironment in patients with melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.